Opiant Pharmaceuticals (STU:8OP) EV-to-EBITDA : -2.49 (As of May. 11, 2024)

Opiant Pharmaceuticals EV-to-EBITDA Chart

Opiant Pharmaceuticals Annual Data
	Trend	Jul12	Jul13	Jul14	Jul15	Jul16	Jul17	Dec18	Dec19	Dec20	Dec21
EV-to-EBITDA		Get a 7-Day Free Trial					2.74	-1.46	2.58	-3.18	22.21

Opiant Pharmaceuticals Quarterly Data
	Oct17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EV-to-EBITDA	Get a 7-Day Free Trial															25.58	22.21	-19.82	-2.07	-1.19

Competitive Comparison of Opiant Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Opiant Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opiant Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's EV-to-EBITDA falls into.

Opiant Pharmaceuticals EV-to-EBITDA Calculation

Opiant Pharmaceuticals's EV-to-EBITDA for today is calculated as:

Opiant Pharmaceuticals's current Enterprise Value is €73.01 Mil.
Opiant Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-29.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opiant Pharmaceuticals  (STU:8OP) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Opiant Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

Opiant Pharmaceuticals's share price for today is €21.20.
Opiant Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Opiant Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Opiant Pharmaceuticals (STU:8OP) Business Description